Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Taconic Farms has reached an agreement to buy an 80.1% stake in Artemis Pharmaceuticals from its parent company Exelixis. Artemis will change its name to TaconicArtemis.
Subscribe to our email newsletter
In 2005, Artemis and Taconic established a strategic alliance which combined Artemis’s technology platform in mouse genetics and genomics with Taconic’s expertise in breeding mice and rats, quality control and global marketing and distribution.
Sam Phelan, Taconic’s CEO, said: “We have already proven that combining the strengths of Artemis and Taconic under the alliance significantly speeds up the delivery of genetically modified mice to clients. The acquisition will enable us to continue to improve this service by more closely aligning our sales, marketing and production operations.
“The alliance will also benefit from the continued involvement of Exelixis as a shareholder and member of the Taconic Artemis governing body. Our companies know how to work together and utilize our respective talents and expertise’s to design and deliver the critical mouse models needed by researchers to conquer human diseases.”